Drug Pricing
The process will pit breast cancer treatment competitors Kisqali and Verzenio against each other as CMS develops pricing offers.
Conclusion of India-EU talks sets ground for a free trade agreement to cut pharma tariffs, in turn lowering the cost for novel drugs like Novo’s obesity treatment Wegovy, though an investment protection agreement – likely influencing data exclusivity – will be concluded later.
Despite group sales growth and its pharmaceutical division revenue weathering a big loss of exclusivity, J&J experienced stock price weakness after its fourth-quarter results announcement as geopolitical tensions depressed stock markets again.
Industry leaders predict pricing uncertainty will force companies to abandon blanket global launches. However, AI platforms will reshape commercial execution and new access models will break down barriers limiting patient reach.
BMS tells Scrip it will continue to seek legal recourse even as Zydus Lifesciences launches the world’s first cut-price nivolumab biosimilar in India following a Delhi High Court division bench ruling in favor of the Indian company
The Swiss pharma co-authored a “call for bold life sciences investment” with the Eurasia Group, critiquing global trade policy and advocating “innovation-friendly” reforms, including moving away from reference pricing.
The plan does not include many details but is intended to help Congress draft legislation ensuring Most Favored Nation drug pricing agreements can be made, as well as implement measures intended to lower insurance premiums.
The announced deal means that of 17 companies the White House notified in July, only AbbVie and Regeneron have not yet made a deal.
With a starter dose price of $149 a month for self-payers, oral Wegovy will be available directly from Novo Nordisk and through telehealth providers and large pharmacy chains.
There has not been a dull moment in the biopharma sector this year. With just a day left, and in no particular order, Scrip takes a look at five of the biggest stories of 2025.
Industry veterans put themselves in Novo’s shoes, suggesting pricing manoeuvres and tactical measures to blunt competition in India post semaglutide’s LOE in 2026. There’s also court action to watch.
Amgen, BMS, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck & Co., Novartis and Sanofi will reduce prices of some drugs for Medicaid and offer reduced pricing through direct-to-patient platforms, among other concessions. In exchange, they will be exempted from tariffs.
Ozempic debuts in India, priced in the ‘affordable zone’ for the country's population, with Novo Nordisk hoping the blockbuster drug can hold its own post impending loss of exclusivity in the country next year.
Sun launches tildrakizumab, its star psoriasis therapy in India seven years after US FDA approval at what’s seen as a carefully calibrated price point. Can it ruffle entrenched products like secukinumab?
The Trump administration leveraged tariffs to convince the UK National Health Service to increase prices for new medicines by 25%.
Under the Inflation Reduction Act, CMS negotiated lower Medicare Part D prices for 15 drugs with 2027 costs 38%-85% lower than 2024 list prices, but analyses of net prices paid last year show smaller discounts.
The second cycle of IRA price negotiations could result in price cuts as high as 85% to the 2024 list prices, but the mean discount across the 15 negotiated drugs appears similar to the previous round.
US FDA approval of the intrathecal formulation of Zolgensma means many more patients with spinal muscular atrophy will be eligible for the gene therapy.
Redemplo is Arrowhead’s first commercial product, and the drug will enter a competitive market. Arrowhead and Ionis have taken different pricing paths, however.
Ohtuvayre is off to a great start in the US but Verona's new owner MSD has pulled the file from the EMA for the closely-watched chronic obstructive pulmonary disease drug.